Term ends Mar 13, 2039 · Low confidence
20-year base term ends Mar 13, 2039
Held by Tusk Therapeutics Ltd.
Filed Feb 5, 2020 as application 16/782,440 · Granted Oct 31, 2023
Base term, 20 years from filing
Today
2019
2039
Clock starts
Mar 13, 2019
Mar 13, 2019
Term ends
Mar 13, 2039
Mar 13, 2039
Granted
Oct 31, 2023
Oct 31, 2023
base term
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,745,485, to Mar 13, 2039. The term already ends on or before that date, so the cap shortened nothing.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 3 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 13, 2019, when application 16/352,717, the earliest non-provisional in its chain, was filed (this one was filed Feb 5, 2020); a parent in its chain could not be resolved (the next row) | Mar 13, 2039 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,745,485) | resolves to Mar 13, 2039, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Further caveats on record | The record names parents not resolved: 16352717 | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | Mar 13, 2039 | Low confidence |
This family
| US 10,745,485 | In force Mar 2039 | Mar 2039 |
| US 11,802,160 | this patent Mar 2039 | Mar 2039 |
| Application 18/470,875 | Abandoned not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 23, 2022 Reel 61199, frame 966 | Goubier, Anne; Corzo, Beatriz Goyenechea; Salimu, Josephine; Moulder, Kevin; Merchiers, Pascal; Brown, Mark | Tusk Therapeutics Ltd. | Assignment of Assignor's Interest |
| Sep 23, 2022 Reel 61200, frame 1 | Geoghegan, James; Prinz, Bianka | Adimab, LLC | Assignment of Assignor's Interest |
| Sep 23, 2022 Reel 61200, frame 27 | Adimab, LLC | Tusk Therapeutics Ltd. | Assignment of Assignor's Interest |
| Sep 23, 2022 Reel 61200, frame 48 | University College London | Cancer Research Technology Limited; Tusk Therapeutics Ltd. | Assignment of Assignor's Interest |
| Sep 23, 2022 reel/frame not recorded | University College London | Cancer Research Technology Limited | Assignment of Assignor's Interest |
| Sep 23, 2022 reel/frame not recorded | University College London | Tusk Therapeutics Ltd. | Assignment of Assignor's Interest |
| Sep 14, 2023 Reel 64899, frame 188 | Quezada, Sergio | University College London | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2039
Term ends Mar 13, 2039. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,745,485, ends no earlier than this term, so it caps nothing.
Citations
7
later US patents cite this one
That is top 10% of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.